Huntington’s disease treatment research is moving quickly. This page helps families, advocates, donors, and communities follow what is happening in the treatment pipeline and understand what each development may mean for access.
What We Track
We follow credible updates about HD treatments and access, including clinical-trial progress, research findings, regulatory submissions, FDA review and decisions, insurance and Medicare coverage developments, and treatment availability.
Why This Matters
A trial result is not an approval. An approval is not the same as insurance coverage. Coverage is not always the same as timely access. We share dated updates so families can follow the story over time and prepare for the questions that come next.
Find a Specific Treatment
Search the site by treatment name, or start with one of our dated treatment updates:
HD Treatment News and Pipeline Updates
- 30 years later scientists discover a drug to heal fatal brain disease – The Times of India
- Mixed results from Huntington’s gene therapy trial after four years – Progress Educational Trust
- January 2026: This Month in Huntington’s Disease Research – HDBuzz
- Going boldly: First person treated in Phase 1 clinical trial by Alnylam Pharmaceuticals – HDBuzz – Huntington’s disease research news.
- UniQure tumbles with latest data for Huntington’s gene therapy – BioPharma Dive
- September 2026: This month in Huntington’s disease research – HDBuzz – Huntington’s disease research news.
- September 2026: This month in Huntington’s disease research – HDBuzz
- Oral therapy may slow progression in early-stage Huntington’s disease – Huntington’s Disease News
- Skyhawk’s SKY-0515 Shows Significant Clinical Benefit in 15-Month Huntington’s Disease Study – BioPharma APAC
- Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease Patients – The Manila Times
- Skyhawk’s SKY-0515 shows 1.59-point cUHDRS advantage at 15 months in Huntington’s disease – AllSci
- Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease Patients – PR Newswire
- Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease Patients – PR Newswire
- What to expect from UniQure’s upcoming Huntington’s gene therapy readout – STAT
- Developer now seeking approval of Huntington’s gene therapy in US, UK – Huntington’s Disease News
This archive includes coverage from multiple sources and treatment areas. Use the pagination controls to browse older items. Headlines link to the original source. Inclusion here does not mean that Take Back Tomorrow HD endorses a treatment, predicts approval, or provides medical advice.
Stay Informed
If you see an important HD treatment development that should be considered for this page, contact us. For personal medical questions, treatment decisions, or clinical-trial eligibility, speak with your treating physician or qualified healthcare team.